Madrid, Spain.Langley RG, Gooderham M, Papp KA, et al. Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 2. Poster presented at: 28th European Academy of Dermatology and Venereology Congress
Advertisement
Articles by Madrid, Spain.Langley RG, Gooderham M, Papp KA, et al. Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 2. Poster presented at: 28th European Academy of Dermatology and Venereology Congress
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Linking Insured Adults to Behavioral Health Care: A Cost-Saving Solution
2
Diabetes Tied to Increased Risk of Sudden Cardiac Death
3
Evaluating Adalimumab Biosimilar Switch Impact on Disease Flares, Tolerability
4
FDA Grants Full Approval to Pirtobrutinib for CLL/SLL
5
